Skip to main
  1. Stocks
  2. Kyntra Bio Inc
  3. Forecast
KYNB

KYNB Stock Forecast & Price Target

KYNB Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyntra Bio is viewed favorably because it has made a disciplined strategic reset by discontinuing the FG-3246 and FG-3180 oncology programs after insufficient efficacy, which should save upwards of $20 million over the next two years and allow capital to be concentrated on roxadustat. Roxadustat is the more compelling fundamental asset, with preliminary activity in anemia associated with lower-risk MDS, including an exploratory signal in high transfusion burden patients, a favorable safety and tolerability profile, and a pivotal Phase 3 plan targeting about 200 patients with an oral dosing regimen. The balance sheet also supports the thesis, as the company reported $44.1 million in cash with expected runway into 2028, while the royalty restructuring lifted pro forma cash to approximately $53 million and extended runway into 4Q27, improving execution flexibility.

Bears say

Kyntra Bio is facing a materially weaker outlook because a planned interim analysis of its FG-3246 Phase 2 trial showed insufficient efficacy, undermining confidence in its oncology pipeline. The company has now discontinued development of both FG-3246 and FG-3180, which reduces the number of potential value drivers and raises the risk that future clinical catalysts will be limited. With the pipeline already concentrated in high-risk development-stage assets, this setback materially worsens the fundamental case by shrinking optionality and increasing reliance on remaining programs to offset the loss.

KYNB has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyntra Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

KYNB Analyst Forecast & Price Prediction

Get the latest KYNB stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in KYNB

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyntra Bio Inc (KYNB) Forecast

Analysts have given KYNB a Strong Buy based on their latest research and market trends.

According to 5 analysts, KYNB has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyntra Bio Inc (KYNB)


KYNB Analyst Forecast & Price Prediction

Get the latest KYNB stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in KYNB

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KYNB stock data and trends